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A B S T R A C T   
Dimethyltryptamine (DMT), an endogenous ligand of sigma-1 receptors (Sig-1Rs), acts against systemic hypoxia, 
but whether DMT may prevent cerebral ischemic injury is unexplored. Here global forebrain ischemia was 
created in anesthetized rats and aggravated with the induction of spreading depolarizations (SDs) and subse-
quent short hypoxia before reperfusion. Drugs (DMT, the selective Sig-1R agonist PRE-084, the Sig-1R antagonist 
NE-100, or the serotonin receptor antagonist asenapine) were administered intravenously alone or in combi-
nation while physiological variables and local field potential from the cerebral cortex was recorded. Neuro-
protection and the cellular localization of Sig-1R were evaluated with immunocytochemistry. Plasma and brain 
DMT content was measured by 2D-LC-HRMS/MS. The affinity of drugs for cerebral Sig-1R was evaluated with a 
radioligand binding assay. Both DMT and PRE-084 mitigated SDs, counteracted with NE-100. Further, DMT 
attenuated SD when co-administered with asenapine, compared to asenapine alone. DMT reduced the number of 
apoptotic and ferroptotic cells and supported astrocyte survival. The binding affinity of DMT to Sig-1R matched 
previously reported values. Sig-1Rs were associated with the perinuclear cytoplasm of neurons, astrocytes and 
microglia, and with glial processes. According to these data, DMT may be considered as adjuvant pharmaco-
logical therapy in the management of acute cerebral ischemia.   
1. Introduction 
N,N-Dimethyltryptamine (DMT) is a natural indole alkaloid found in 
plants (e.g. Psychotria viridis and Diplopterys cabrerana) and is known for its 
psychedelic effects when ingested by humans as spiritual medicine or with 
recreative purposes (e.g. ayahuasca brew) (Luna, 2011). Importantly, 
DMT has also been identified as an endogenous trace amine in mammalian 
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tissues (e.g. lung, pineal gland, brain) (Christian et al., 1977; Mandel et al., 
1977; Barker et al., 2013) and body fluids (urine, blood plasma and ce-
rebrospinal fluid) (Barker et al., 2012). The actual production of DMT 
from the amino acid tryptophan in mammalian tissues is supported by the 
(co-)localization of the enzymes aromatic-L-amino acid decarboxylase 
(AADC) and indolethylamine-N-methyltransferase (INMT) implicated in 
DMT biosynthesis (Mavlyutov et al., 2012; Carbonaro and Gatch, 2016; 
Dean et al., 2019). DMT, however, is rapidly biodegraded by monoamine 
oxidases (MAO), which may be the reason for the very low endogenous 
DMT concentration measured (e.g. ng/mL or ng/g tissue). Still, DMT may 
be encapsulated in neurotransmitter storage vesicles at concentrations 
regarded to be pharmacologically relevant (Carbonaro and Gatch, 2016). 
The physiological and pathophysiological role of endogenous DMT 
has been the subject of ongoing debate and speculations. Psychedelic 
and behavioral effects (Jenner et al., 1978), a potential role in psychi-
atric disorders (Daumann et al., 2010) and altered states of conscious-
ness (Strassman, 2001) have all been attributed to naturally occurring 
DMT. Besides all of these elusive associations, investigators have 
recently turned their attention to the prospective general tissue pro-
tective (Frecska et al., 2013), and specific neuroprotective potential of 
the substance (Szabo et al., 2016; Nardai et al., 2020). DMT has been 
claimed to be produced at increased concentration in the rodent brain 
when exposed to environmental stress delivered by electrical shock 
(Barker et al., 1981). More importantly, the DMT content of the rat brain 
was found elevated after experimental cardiac arrest (Dean et al., 2019). 
Recently, DMT was shown to protect human primary iPSC-derived 
cortical neurons against hypoxia, coincident with the reduction of 
hypoxia-inducible factor-1 (HIF-1) expression and function (Szabo et al., 
2016). Further, DMT injected intraperitoneally limited infarct size in a 
rodent model of focal cerebral ischemia, and facilitated the recovery of 
motor function following ischemic injury (Nardai et al., 2020). Finally, 
DMT was suggested to achieve notable anti-inflammatory effects (Szabo 
et al., 2014), because the serum levels of pro-inflammatory cytokines 
(TNF-α, IL-1β, IL-6) were found to be decreased in the presence of DMT 
in the above rat focal cerebral ischemia model (Nardai et al., 2020). 
The pharmacological mechanisms of DMT action have been exten-
sively explored, revealing a complex interaction with numerous 
signaling pathways including biogenic amine receptors, (Ray, 2010), 
uptake transporters (Blough et al., 2014), and trace amine-associated 
receptors (Bunzow et al., 2001). In addition, fundamental evidence 
has been gathered that DMT acts as an endogenous sigma-1 receptor 
(Sig-1R) agonist (Fontanilla et al., 2009). Sig-1Rs are intracellular 
receptors localized to the segment of the endoplasmic reticulum (ER) 
membrane, which is apposed to the mitochondrial outer membrane (the 
mitochondria-associated ER membrane, MAM). Via precise molecular 
machinery, Sig-1Rs control Ca2+ trafficking between the MAM and 
mitochondria, regulate the expression of specific potassium channels, 
suppress the generation of reactive oxygen species, and ultimately 
promote cell survival under stress (Hayashi, 2015; Penke et al., 2018). A 
wealth of experimental data suggests that Sig-1R activation yields 
neuroprotection in ischemic stroke. For example, fluvoxamine, a potent 
antidepressant with high affinity for Sig-1R has been demonstrated to 
suppress ER stress-related apoptosis, reduce infarct size after focal ce-
rebral ischemia, and alleviate ischemia-linked motor dysfunction in 
mice (Omi et al., 2014; Sato et al., 2014). These results have been 
confirmed by increased apoptotic neuronal death in Sig-1R knockout 
mice exposed to global forebrain ischemia, and the suppression of 
ischemia-induced apoptosis in wild-type mice by the administration of 
PRE-084, a selective Sig-1R agonist pharmacon (Zhao et al., 2019). 
Coincidentally, a significant upregulation of Sig-1R has been linked to 
the ischemic penumbra (Zhang et al., 2017). Collectively, these data are 
highly suggestive that Sig-1R activation may be exploited for the pur-
pose of ischemic neuroprotection. 
Here we set out to explore whether DMT administration achieves 
neuroprotection via Sig-1R activation in the acute phase of experi-
mental, transient, cerebral forebrain ischemia, which we aggravated by 
the recurrent induction of spreading depolarizations (SD) (Somjen, 
2001) and a subsequent transient hypoxic episode. We have chosen to 
induce SDs and an episode of anoxia superimposed on global cerebral 
ischemia to increase the metabolic stress to a level which may cause 
acute neurodegeneration and is relevant to observe DMT action. Inci-
dentally, SD initiates the fission of the ER (the intracellular host of 
Sig-1Rs), which may serve as a target of neuroprotection (Kurcharz and 
Lauritzen, 2018). The physiological impact of administered DMT was 
evaluated by the assessment of cerebral blood flow (CBF) variations and 
the characteristic features of SD, a neurophysiological phenomenon that 
had been recognized to accelerate the conversion of the ischemic pen-
umbra to the infarcted region (Hartings et al., 2017). Furthermore, SD is 
a relevant target of investigation in the context of neuroprotection, 
because SD inhibition has been repeatedly proposed as an effective 
approach for tissue salvage in brain injury (Carlson et al., 2018, 2020; 
Klass et al., 2018; Varga et al., 2020). As a final point in our experiments, 
DMT-related neuroprotection was evaluated with comprehensive his-
tological examination. 
Abbreviations 
2D-LC-HRMS/MS two-dimensional liquid chromatography coupled 
to quadrupole-Orbitrap mass spectrometry 
2VO two vessel occlusion 
4-HNE 4-hydroxynonenal 
5-HTR serotonin receptor 
AADC aromatic-L-amino acid decarboxylase 
aCSF artificial cerebrospinal fluid 
ANOVA analysis of variance 
ATP adenosine triphosphate 
AUC area under the curve 
BSA bovine serum albumin 
CBF cerebral blood flow 
CC3 cleaved caspase 3 
DAB diaminobenzidine 
DC direct current 
DG dentate gyrus 
DMSO dimethyl sulfoxide 
DMT N,N-dimethyltryptamine 
EDTA ethylenediamine tetraacetic acid 
ECoG electrocorticogram 
ER endoplasmic reticulum 
GFAP glial fibrillary acidic protein 
HIF-1 hypoxia-inducible factor 1 
Iba-1 ionized calcium-binding adapter protein 
INMT indolethylamine N-methyltransferase 
i.m. intramuscular 
i.v. intravenous 
LDF laser-Doppler flowmetry 
MABP mean arterial blood pressure 
MAM mitochondria-associated ER membrane 
MAO monoamine oxidase 
NeuN neuronal nuclear protein 
NMDA N-methyl-D-aspartate 
PBS phosphate buffered saline 
PFA paraformaldehyde 
SD spreading depolarizations 
Sig-1R Sigma-1 receptor 
TBS Tris-buffered saline  
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To confirm the role of Sig-1Rs in the DMT-linked effects, we 
measured the binding affinity of DMT to Sig-1Rs in rat brain tissue and 
we evaluated the response to DMT in the presence of the selective Sig-1R 
agonist PRE-084 or the Sig-1R antagonist NE-100. To discriminate the 
potential contribution of serotonin receptors to DMT-related effects, 
asenapine, an antagonist of a wide range of serotonin receptors (Shadid 
et al., 2009), was applied alone, or in combination with DMT. Next, to 
confirm that DMT infused over the experimental protocol accumulated 
in the blood and brain to a pharmacologically relevant concentration, 
we determined the DMT content in these tissues with an analytical 
chemical method (Körmöczi et al., 2020). Finally, we confirmed the 
co-localization of Sig-1Rs with neurons, astrocytes and microglia cells, 
as potential cellular targets of DMT treatment. 
2. Materials and methods 
The ethical approach conformed to previously reported guidelines 
(Szabó et al., 2019; M. Tóth et al., 2020; Varga et al., 2020), and the 
experiments are reported in compliance with the ARRIVE guidelines 
(Kilkenny et al., 2010). The experimental procedures were approved by 
the National Food Chain Safety and Animal Health Directorate of 
Csongrád County, Hungary. The procedures were performed according 
to the guidelines of the Scientific Committee of Animal Experimentation 
of the Hungarian Academy of Sciences (updated Law and Regulations on 
Animal Protection: 40/2013. (II. 14.) Gov. of Hungary), following the 
EU Directive 2010/63/EU on the protection. 
The animals were housed according to standrad conditions reported 
earlier (Szabó et al., 2019; M. Tóth et al., 2020; Varga et al., 2020). 
Young adult, male Sprague-Dawley rats (Charles River Laboratories, 
340 ± 37 g, n = 69) were used in this study. Standard rodent chow and 
tap water were supplied ad libitum. The animals were housed under 
constant temperature, humidity, and lighting conditions (23∘C, 12:12 h 
light/dark cycle, lights on at 7 a.m.). 
The estimation of sample size adhered to previously applied princi-
ples (Szabó et al., 2019; Varga et al., 2020). The designed rate of the 
seven groups of the in vivo experiment (untreated and treated) was 1. 
The necessary number of animals in each group was at least 6 to support 
80% power (β = 20% risk of second species), which was calculated based 
on the standard deviation of electrophysiological and hemodynamic 
parameters in earlier studies and the presumed differences between the 
means of groups. The calculations and statistical analyses were con-
ducted in SPSS version 20 (Vanderbilt University, U.S.A.) and were also 
run in GPower 3.1 (Heinrich Heine University of Düsseldorf, Germany). 
2.1. Surgical procedures 
The preparation has followed previously establihsed guidelines 
(Szabó et al., 2019; Varga et al., 2020). On the day of the experiments, 
animals were anesthetized with 1.5–2% isoflurane in N2O:O2 (3:2), and 
were allowed to breathe spontaneously through a head cone during 
surgical interventions (n = 56). Body temperature was kept at 37.2 ◦C by 
a feedback controlled heating pad (Harvard Apparatus, Holliston, MA, 
U.S.A.). In order to avoid the production of airway mucus, atropine was 
administered (0.1%, 0.05 mL; i.m.) shortly before surgical procedures. 
The left femoral artery was cannulated for blood sampling and the 
continuous monitoring of mean arterial blood pressure and heart rate 
(MABP, Mikro-Tip BP Foundation System, ADInstruments, Australia). 
The adjacent femoral vein was also cannulated for the administration of 
drugs. 
Actual surgical procedures have also replicated previously estab-
lished methods (Szabó et al., 2019; Varga et al., 2020). For the later 
initiation of incomplete global forebrain ischemia, a midline incision 
was made in the neck and both common carotid arteries were carefully 
separated from the vagal nerves. Lidocaine (1%) was administered 
topically before opening the skin and each tissue layer underneath. A 
surgical thread used as occluder was looped around each artery for the 
later occlusion. All rats were placed prone in a stereotaxic apparatus. 
The skin above the skull and the temporal muscle were retracted from 
the underlying left parietal and temporal bones. Two cranial windows 
(~3 × 3 mm) 1 mm apart were prepared over the right parietal cortex (3 
mm from bregma and 5 mm lateral from the sagittal suture) (Fig. 1). A 
high-precision electrical drill (ProLab Basic, Bien Air 810, Switzerland) 
was used to thin the bone under saline cooling, and the remaining soft 
bone layer was gently peeled away to reveal the dura surface. The dura 
was then carefully opened in each craniotomy. The rostral window was 
later used for data acquisition (i.e. electrophysiology and CBF mea-
surement) while the caudal window served SD elicitation (Fig. 1). The 
cranial windows were constantly kept moist by artificial cerebrospinal 
fluid (aCSF; mM concentrations: 126.6 NaCl, 3 KCl, 1.5 CaCl2, 1.2 
MgCl2, 24.5 NaHCO3, 6.7 urea, 3.7 glucose bubbled with 95% O2 and 
5% CO2 to achieve a constant pH of 7.4). 
2.2. Recording of electrophysiological variables 
Electrophysiological data were acquired as reported earlier (Szabó 
et al., 2019; Varga et al., 2020). For the acquisition of the electrocorti-
cogram (ECoG) and slow cortical or direct current (DC) potential, a 
saline-filled (120 mM NaCl) glass capillary microelectrode (20 μm outer 
tip diameter) was inserted 700 μm deep into the right somatosensory 
cortex. An Ag/AgCl reference electrode was implanted under the skin of 
the animal’s neck. The electrophysiological signals were recorded via a 
high input impedance pre-amplifier (NL102GH, NeuroLog System, 
Digitimer Ltd., United Kingdom), connected to a differential amplifier 
(NL106, NeuroLog System, Digitimer Ltd., United Kingdom) with asso-
ciated filter (ECoG filtered in wideband scale: 0.5–35 Hz, DC filtered in 
DC mode; <0.5 Hz) and conditioner systems (NL125, NL144, NL530, 
NeuroLog System, Digitimer Ltd., United Kingdom). Line frequency 
noise (50 Hz) was removed by a high-quality noise eliminator (HumBug, 
Quest Scientific Instruments Inc., Canada). The electrical signals along 
with MABP were digitalized at a sampling frequency of 2 kHz by a 
PowerLab data acquisition device (ADInstruments, Australia) controlled 
through a dedicated software written in LabChart 8 (ADInstruments, 
Australia). 
2.3. Monitoring of local cerebral blood flow 
CBF measurements were conducted as reported earlier (Szabó et al., 
2019). Laser-Doppler flowmetry (LDF) was used to record changes in 
local CBF with ischemia/reperfusion, and associated with SD events. A 
laser-Doppler needle probe (Probe 403 connected to PeriFlux 5000; 
Perimed AB, Sweden) was positioned above the parietal cortex. The 
ideal position of the LDF probe was identified prior to the actual 
experimental protocol: the probe was positioned over the region where 
the baseline perfusion varied closely around 300 perfusion units (PFU), 
as near as possible to the tip of the glass microcapillary, and avoiding 
visible pial blood vessels. The LDF signal was digitalized and acquired, 
together with the DC potential and ECoG, essentially as described above. 
2.4. Pharmacological treatment 
All drugs were dissolved in physiological saline, administered at a 
dose of 1 mg/kg/h (Maurice et al., 1995; Ghanbari et al., 2009; Sato 
et al., 2014; Nardai et al., 2020), and infused through the left femoral 
vein continuously throughout the experimental protocol (Fig. 1). 
Although DMT has poor solubility in aqueous media, intensive vortexing 
at 37 ◦C resulted in a transparent solution at the low concentration used. 
The concentration of the DMT solution was 0.18 mg/mL (0.956 mM). 
The following treatments were applied: DMT (Lipomed AG, 
Switzerland) alone (n = 7), the highly selective Sig-1R agonist PRE-084 
(Sigma-Aldrich, U.S.A.) alone (n = 8), the selective Sig-1R antagonist 
NE-100 (Sigma-Aldrich, U.S.A.) alone (n = 6) or in combination with 
DMT (n = 6), and the non-subtype specific serotonin receptor (5-HTR) 
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antagonist asenapine (Sigma-Aldrich, U.S.A.) alone (n = 6) or in com-
bination with DMT (n = 6). Vehicle (i.e. physiological saline) served as 
control for the treatments (n = 7). NE-100 and DMT or asenapine and 
DMT were used in combination to test the receptor-specificity of DMT. 
2.5. Experimental protocol 
The experimental protocol was initiated 30–60 min after completion 
of the preparation. After a baseline period (5 min), cerebral ischemia 
was induced by the occlusion of both common carotid arteries (two 
vessel occlusion: 2VO). Successful 2VO was confirmed by a sharp drop of 
CBF below 50% of baseline, as reported earlier (Menyhárt et al., 2017; 
Szabó et al., 2019). Ischemia induction was not followed by spontaneous 
SD occurrence, probably because the hypoperfusion threshold to trigger 
SD (Menyhárt et al., 2017) was not reached. The administration of DMT, 
PRE-084, or vehicle was initiated through the femoral vein immediately 
after completion of the ischemia induction, with the aid of a micro-
injector syringe pump (CMA/100 Micro Injection Pump, Carnegie 
Medicin, Sweden). Due to the dead volume in the tubing, it could have 
taken a few minutes before the DMT solution actually reached the brain. 
Since the common carotid arteries had been occluded by that time, 
blood flow compensation from the posterior supplying vessels was ex-
pected to be the route of drug delivery to the brain. Residual CBF during 
ischemia varied around 40% (see: Results – Physiological variables), 
which was considered sufficient for drug delivery. In the case of DMT 
co-application with NE-100 or asenapine, the infusion of NE-100 or 
asenapine began 10 min before ischemia induction to act on receptors 
before DMT application. The intravenous (i.v.) infusion of the drugs was 
continuous and maintained until the end of the experiment. 
As further metabolic challenge superimposed on ischemia, three SD 
events were triggered at an inter-SD interval of at least 15 min with a 1 
M KCl-soaked cotton ball placed on the cortex in the caudal craniotomy 
(Farkas et al., 2011), starting 10 min after 2VO onset (Fig. 1). The cotton 
ball was removed and the craniotomy rinsed with aCSF after each SD 
event. After the three SDs had subsided, the ischemic insult was further 
aggravated by an episode of transient hypoxia (maximum of 1 min) 
achieved by the controlled withdrawal of O2 from the anesthetic gas 
mixture. The duration of hypoxia had been determined in pilot experi-
ments. Longer episodes of hypoxia caused the failure of cardiac function, 
therefore we adjusted hypoxia duration according to the tolerance of 
each animal: hypoxia was maintained in the presented experimental 
protocol as long as arterial pressure (monitored continuously live) was 
stable enough for prospective recovery from the insult. The hypoxic 
episode was followed by reoxygenation and the prompt release of the 
common carotid arteries to afford cerebral reperfusion for another hour. 
2.6. Immunocytochemistry 
Immunolabeling followed procedures that are in routine use in our 
lab (M. Tóth et al., 2020; Varga et al., 2020). For all staining protocols, 
antibody specificity was confirmed by performing the staining in the 
absence of the primary antibody in the solution prepared for the primary 
incubation step. Naïve (n = 3), and vehicle- or DMT-treated rats exposed 
to the full experimental protocol (i.e. 2 h after ischemia induction and 1 
h after reperfusion induction; n = 4/4) were transcardially perfused 
with ice-cold physiological saline followed by 4% paraformaldehyde 
(PFA) under deep anesthesia (5%, i.p., 500 mg/kg). The brains were 
removed, stored in 4% PFA at 4 ◦C overnight, and cryoprotected in 30% 
sucrose in phosphate buffered saline (PBS). Coronal, 20 μm thick fore-
brain sections were cut with a freezing microtome (Leica CM, 1860 UV, 
Leica, Germany). 
Apoptotic cell death was characterized with permanent immunocy-
tochemical staining of cleaved caspase-3 (CC3), ferroptotic injury by 4- 
hydroxinonenal (4-HNE), whereas neuronal loss was identified with the 
neuron marker neuronal nuclear protein (NeuN), and astrocyte damage 
with the astrocyte marker glial fibrillary acidic protein (GFAP) on 
selected coronal slices (bregma +1, − 3 and − 6 mm, Paxinos and Watson 
atlas coordinates; three slices per plane). Microglial activation was 
detected with ionized calcium-binding adapter protein (Iba-1) immu-
nohistochemistry. In all cases, endogenous peroxidases were blocked 
with 5% H2O2, nonspecific protein-binding sites were blocked with 5% 
normal goat serum (Merck, Kenilworth, U.S.A.), and slices were per-
meabilized with 0.5% Triton X-100 (Merck, Kenilworth, U.S.A.) in Tris- 
buffered saline (TBS). Slices were incubated with rabbit anti-CC3 
(Abcam, ab13847, 1:300), mouse anti-4-HNE (Abcam, ab48506, 
1:100), rabbit anti-NeuN (Abcam, ab177487, 1:300), mouse anti-GFAP 
(Abcam, ab4648, 1:1000) or rabbit anti Iba-1 (Wako, #019–19741, 
1:3000) overnight at 4 ◦C. The subsequent steps of incubation included 
an enhancer reagent for 1 h at room temperature, and horseradish- 
peroxidase-linked secondary antibody for 3 h at room temperature, 
both being components of the Polink-2 Plus HRP Detection Kit (for 
rabbit or mouse primary antibody with diaminobenzidine (DAB) chro-
mogen, D39–18 for rabbit and D37-18 for mouse, GBI Labs, U.S.A.). The 
staining was visualized with DAB. The slices were mounted on micro-
scopic slides with Eukit® (Merck, U.S.A.) and photomicrographs were 
obtained with a Nikon-DS Fi3 camera attached to a Leica DM 2000 Led 
Fig. 1. Graphical illustration of the experimental protocol. a, In the preparation, black circles indicate the position of the two open cranial windows (3 mm caudal 
from bregma and 5 mm lateral from the sagittal suture), created for the recording of the electrocorticogram (ECoG), direct current (DC) potential and cerebral blood 
flow (CBF) with laser-Doppler flowmetry (rostral window) and the experimental elicitation of spreading depolarizations (SD) with KCl (caudal window). b, The 
schematic drawing illustrates the subsequent phases of the experimental protocol. After the initiation of global forebrain ischemia, the i.v. infusion of either of the 
Sig-1R agonists (DMT or PRE-084) or their vehicle was initiated and maintained until the termination of the experiment. When the Sig-1R or the serotonin receptor 
(5-HTR) antagonists NE-100 or asenapine were applied, their i.v. infusion was initiated before ischemia onset. Subsequently, SDs were triggered at the ipsilateral 
cerebral cortex, then O2 was partially and briefly withdrawn from the anesthetic gas mixture to aggravate ischemia further by transient hypoxia. After an hour of 
reperfusion, the brains were removed under deep anesthesia for histological examination. Arterial blood samples were collected repeatedly ( ) for blood gas analysis 
and the measurement of blood plasma DMT content. 
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light microscope (Leica Microsystems GmbH, Germany). 
Finally, in order to identify the cellular and subcellular localization 
of Sig-1Rs, the receptors were co-labeled with NeuN (neuronal marker), 
GFAP (astrocyte marker) and Iba-1 (microglia marker) in slices from a 
naïve animal. Antigens were retrieved with 10-min-long boiling in 6 M 
urea in Tris-HCl buffer (pH 9.5; 80 ◦C, shaking at 300 rpm) (Hayashi 
et al., 2011). All slices were permeabilized with 0.2% Triton X-100 in 
PBS for 30 min. Non-specific protein-binding sites were blocked with 3% 
bovine serum albumin (BSA) for 1 h at room temperature. Slices were 
incubated with primary antibodies overnight at 4 ◦C (anti-Sig-1R: rabbit, 
Abcam, ab53852, 1:500; anti-NeuN: mouse, Millipore, MAB377, 1:250; 
anti-GFAP: mouse, Sigma, G3893, 1:500; anti-Iba-1: mouse, Wako, 
#016–26721, 1:200 in 3% BSA in PBS). Secondary antibodies were 
applied for 1 h at room temperature (anti-rabbit STAR RED; goat, 
Abberior, 1:500 and anti-mouse STAR 580, goat, Abberior, 1:500 for 
NeuN and GFAP-labelling; anti-rabbit Alexa-488, goat, Thermo Fisher 
Scientific, #A11034, 1:500, anti-mouse Alexa-647, donkey, Thermo 
Fisher Scientific, #A32787, 1:500 for Iba-1 labelling) in 1% BSA in PBS. 
Slices were mounted with Mount Solid antifade© (Abberior, Germany). 
Representative epifluorescent (20x) and confocal (100x) images were 
taken of the somatosensory cortex with a Zeiss Axio Observer Z1 
inverted microscope (Carl Zeiss GmbH, Germany) equipped with a laser 
confocal imaging capable Stedycon (Abberior Instruments, Germany), 
and pieced together, re-coloured and processed in ImageJ (National 
Institutes of Health, Bethesda, Maryland, USA) (Schneider et al., 2012). 
2.7. In vitro radioligand binding assay 
PRE-084 (Sig1-R agonist), asenapine (5-HTR antagonist), fluvox-
amine (Sig-1R agonist), (+)-pentazocine (Sig-1R agonist), haloperidol 
(Sig-1R antagonist) and buffer components (TRIS-HCl) were purchased 
from Sigma-Aldrich Kft. (Budapest, Hungary). The radioligand [3H]- 
(+)-pentazocine (specific activity 1.98 TBq/mmol) was prepared in the 
Laboratory of Chemical Biology (BRC, Hungary). Tritium labeling was 
carried out in a self-designed vacuum manifold (Dvorácskó et al., 2019) 
and radioactivity was measured with a Packard Tri-Carb 2100 TR liquid 
scintillation analyzer using Insta Gel scintillation cocktail of Perki-
nElmer. Drugs were dissolved at 100 mM (DMT) or 1 mM (PRE-084, 
(+)-pentazocine, asenapine, fluvoxamine) in dimethyl sulfoxide 
(DMSO) and were stored at − 20 ◦C, and then diluted in the binding 
buffer. 
Preparation of rat brain tissue membrane homogenates was per-
formed according to a previous method (Narita et al., 1996; Ishima et al., 
2014), with a slight modification. Male Sprague–Dawley rats (n = 10, 
250 g) were decapitated in deep anesthesia, and their brains were 
removed rapidly. The brains without cerebellum were homogenized in 
20 vol of ice-cold 50 mM Tris-HCI (pH 8.0 at 25 ◦C), using a Braun 
Teflon-glass homogenizer at the highest speed for 30 s. The homogenate 
was centrifuged at 48.000 g for 10 min at 4 ◦C. The resulting pellet was 
resuspended in 50 mM Tris-HCI buffer (pH 8.0) and recentrifuged. This 
procedure was repeated twice. The final pellet was suspended in 20 vol 
of 50 mM Tris-HCI (pH 8.0) and stored in aliquots at − 80 ◦C. The protein 
content of the samples was measured by the Bradford method (Bradford, 
1976) and samples were diluted to obtain the appropriate amount for 
the assay. 
Binding assays for the Sig-1R followed previously establihsed 
methhods with slight modification (Ishima et al., 2014). Samples were 
incubated at 27 ◦C for 120 min in a 50 mM Tris–HCl binding buffer (pH 
8.0) in plastic tubes in a total assay volume of 1 mL that contained 0.5 
mg/mL of membrane protein. Competition binding experiments were 
carried out by incubating rat brain membranes with 3.6 nM of [3H] 
(+)-pentazocine (Kd = 13.1 nM) in the presence of increasing concen-
trations (10− 11–10− 3 M) of various competing unlabeled ligands. 
Non-specific binding was determined in the presence of 10 μM halo-
peridol. The incubation was terminated by diluting the samples with 
ice-cold wash buffer (50 mM of Tris–HCl, pH 8.0), followed by repeated 
washing and rapid filtration through Whatman GF/B glass fiber filters 
(Whatman Ltd., Maidstone, England) presoaked with 0.1% poly-
ethyleneimine. Filtration was performed with a 24-well Brandel Cell 
Harvester (Gaithersburg, MD, U.S.A.). Filters were air-dried and 
immersed into Ultima Gold MV scintillation cocktail, and then radio-
activity was measured with a TRI-CARB 2100 TR liquid scintillation 
analyzer (Packard, PerkinElmer, Waltham, MA, U.S.A.). 
2.8. Measurement of exogenous DMT in rat tissue 
Because the enzymatic degradation of DMT is rapid, we set out to 
confirm that DMT supplied to the animals was present at detectable 
levels and sufficient concentration in the blood plasma and brain to 
potentially achieve neuroprotection. Blood samples were collected 
through the femoral artery at baseline (i.e. prior to ischemia onset), 
under ischemia, after hypoxia, and under reperfusion (n = 4/4, vehicle/ 
DMT). Full blood was centrifuged promptly in EDTA coated Eppendorf 
tubes (5000 G, 5 min, 4 ◦C, Heraeus Fresco 17 Microcentrifuge, Thermo 
Scientific, U.S.A.), and supernatant plasma (0.2 mL) was separated into 
another Eppendorf vial. To collect brain tissue samples, the animals (n 
= 4/4, vehicle/DMT) were transcardially perfused with ice-cold physi-
ological saline under deep anesthesia (5%, i.p., 500 mg/kg) at the end of 
the experimental protocol to wash out any blood from the brain. The full 
brains were quickly removed, snap-frozen in liquid nitrogen, and stored 
at − 70 ◦C until further processing. The DMT content of blood plasma 
and brain tissue was measured by using heart-cutting two-dimensional 
liquid chromatography coupled to quadrupole-Orbitrap mass spec-
trometry (2D-LC-HRMS/MS)), which is presented in detail in a previous 
study (Körmöczi et al., 2020). 
2.9. Data analysis 
Data analysis was conducted according to establihsed principles 
(Szabó et al., 2019; M. Tóth et al., 2020; Varga et al., 2020). Physio-
logical variables (i.e. DC potential and MABP) were simultaneously ac-
quired, displayed live, and stored using a personal computer equipped 
with the software LabChart 8 (ADInstruments, Australia). Data analysis 
was assisted by the inbuilt instructions of the software AcqKnowledge 
4.2 for MP 150 (Biopac Systems, Inc., Goleta, U.S.A.). Blinding data 
analysis was intended by assigning codes to files and recordings, which 
do not reveal the experimental condition (i.e., date of the experiment). 
The experimental data were not processed in cases the animals died 
during SD elicitation or due to the hypoxic episode (n = 6, random 
distribution over pharmacological treatments). 
Raw LDF recordings were downsampled to 1 Hz and expressed 
relative to baseline by using the average CBF value of the first 5 min 
(100%) and the recorded biological zero obtained after the termination 
of the experiments (0%) as reference points. Raw DC recordings were 
also downsampled to 1 Hz. 
For SD events, peak amplitude, duration at half amplitude, the rate of 
depolarization and repolarization, and area under the curve (AUC) were 
measured on the DC potential trace of all three SDs. The SDs elicited 
were associated with a prominent hyperemia, rather than spreading 
ischemia, because CBF during ischemia was approximately around the 
upper limit typical of the ischemic penumbra (i.e. 40 % relative to 
baseline). The CBF response to SD tends to be hyperemic under such 
flow conditions, which we have shown earlier (Bere et al., 2014). For 
SD-associated hyperemia, only the second and third SDs were consid-
ered, due to the substantially different CBF response to the first SD. Peak 
amplitude, duration at half amplitude, the rate of depolarization and 
repolarization, and AUC were measured. 
The CC3-labeled and 4-HNE slides were evaluated by manual cell 
counting with the CellCounter plugin of ImageJ (National Institutes of 
Health, Bethesda, Maryland, USA) by two observers blind to the 
experimental design. Cell count was expressed for a unit surface of 1 
mm2. The intensity of the 4-HNE labeling was estimated for the 
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perinuclear cytoplasm of CA1 pyramidal cells and granule cells of the 
dentate gyrus. The cellular cytoplasm of individual labeled cells was 
delineated manually. The density of the labeling was evaluated with 
respect to background by the NIS Elements Advanced Research Software 
(Version 5.20, Nikon) (Nikon Instruments, Tokyo, Japan). Neuronal and 
astrocytic loss was characterized by the estimation of NeuN- or GFAP- 
positive immunolabeling, respectively, in all observed brain regions. 
After masking binary images in ImageJ, the relative surface covered by 
immunopositive cells was expressed. The Iba-1 labelling was evaluated 
with a ramification index as previously described (Tóth et al., 2020). 
Briefly, a lower ramification index value represents a more activated 
microglial status. 
Data and statistical analysis followed previously accepted guidelines 
(Szabó et al., 2019; Varga et al., 2020). Data are given as mean ±
standard deviation (stdev). The results were statistically analyzed with 
the software SPSS (IBM SPSS Statistics for Windows, Version 23.0, IBM 
Corp.). A Grubbs test was applied to identify potential outliers (n = 4, 
random distribution over pharmacological treatments). The normal 
distribution of data sets was evaluated with a Shapiro–Wilk test. In case 
the data showed normal distribution, an independent samples t-test, a 
one-way analysis of variance (ANOVA) or a two-way ANOVA model was 
used, dependent on the type of data set. A Fisher post hoc test was used 
for group comparisons, whenever applicable. In case of nonnormal 
distribution, a Kruskal-Wallis H test was applied, followed by a 
Mann-Whitney U test for group comparisons. Levels of significance were 
defined as p < 0.05* and p < 0.01**. All relevant statistical methods are 
given in each figure legend. 
The results of the competition binding studies are reported as earlier 
(Ishima et al., 2014). Data are provided as means ± standard error of the 
mean (S.E.M.) of at least three independent experiments, each per-
formed in duplicate. In competition binding studies, the inhibitory 
constants (Ki) were calculated from the inflection points of the 
displacement curves using nonlinear least-square curve fitting and the 
Cheng–Prusoff equation, Ki = EC50/(1 + [ligand]/Kd). Ki values of DMT 
in the absence or presence of 10 μM asenapine were compared by un-
paired t-test with two-tailed P value. One sample t-test with a hypo-
thetical value of 100% was applied when specific binding values were 
compared to total specific binding (100%) in receptor binding assays. 
Significance was accepted at P < 0.05 level. All data and curves were 
analyzed by GraphPad Prism 5.0 (San Diego, CA, U.S.A.). 
3. Results 
3.1. Physiological variables 
Blood gases varied in the physiological range throughout the 
experimental protocol, yet these physiological variables significantly 
shifted over the reperfusion period with respect to baseline and 
ischemia/hypoxia. In particular, by the end of the reperfusion period, 
blood pH showed a decreasing tendency (pH 7.27 ± 0.17 vs. 7.31 ± 0.11 
and 7.30 ± 0.12, reperfusion vs. baseline and ischemia/hypoxia; F =
2.525, p < 0.085), pCO2 noticeably increased (42.3 ± 13.6 vs. 33.2 ± 7.6 
and 34.3 ± 10.5 mmHg, reperfusion vs. baseline and ischemia/hypoxia; 
F = 9.102, p < 0.0003**) and pO2 decreased (99.6 ± 24.3 vs. 111.2 ±
17.0 and 108.4 ± 26.6; F = 3.534, p < 0.033*). 
MABP values confirmed sufficiently deep anesthesia. MABP slightly 
elevated during ischemia (83 ± 8 vs. 77 ± 4 mmHg, ischemia vs. 
baseline) and fell due to transient hypoxia (to 66 ± 8 mmHg), at no 
statistical significance over the experimental protocol (F = 3.349, p <
0.127). DMT application had no discernible impact on MABP (F = 0.125, 
p < 0.738) (Fig. 2a). Heart rate was stable throughout the experimental 
protocol (e.g. vehicle group: 331 ± 27, 327 ± 41 and 319 ± 43 bpm, 
baseline, ischemia and reperfusion; F = 0.012, p < 0.918). DMT elevated 
heart rate slightly but not significantly (e.g. reperfusion: 344 ± 19 vs. 
319 ± 43 bpm, DMT vs. vehicle; F = 1.290, p < 0.307). 
Any consequence of DMT application on baseline CBF variation was 
also considered. After ischemia induction, CBF dropped sharply and 
then stabilized at 40.3 ± 4.8% prior to SD1, and at 34.2 ± 10.1% prior to 
the induction of transient hypoxia in the vehicle-treated group (Fig. 2b). 
With hypoxia, perfusion decreased further (to 28.3 ± 5.4%). Reactive 
hyperemia was not obvious as reperfusion was imposed; instead, CBF 
peaked at 70.1 ± 17.8%. DMT did not alter baseline CBF at any time 
point or condition considered (Fig. 2b). 
3.2. The impact of DMT on the evolution of spreading depolarization 
As the suppression of spontaneous, recurrent SDs by pharmacolog-
ical means has emerged as a promising target in ischemic neuro-
protection (Klass et al., 2018; Szabó et al., 2019; Varga et al., 2020), we 
have sought to explore the SD limiting potential of DMT. We have also 
aimed to tackle by pharmacological means whether DMT action may be 
achieved via Sig-1R activation. 
The amplitude of SD was significantly reduced in the presence of 
DMT (− 16.5 ± 4.1 vs. − 20.1 ± 1.3 mV, DMT vs. vehicle) (Fig. 3a–b). 
Fig. 2. Mean arterial blood pressure (MABP) and cerebral blood flow (CBF) variations over the experimental protocol. a, DMT exerted no impact on MABP over the 
experimental protocol. b, While CBF was obviously reduced during ischemia, DMT did not change the CBF baseline variations with respect to the vehicle group. In 
“a” and “b”, data are given as mean ± stdev. A repeated measures model was used for statistical analysis (p < 0.05* and p < 0.01**). 
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Likewise, the rate of depolarization proved to be also slower in the DMT- 
treated group with respect to control (− 2.62 ± 1.28 vs. − 3.48 ± 0.94 
mV/s, DMT vs. vehicle) (Fig. 3c). Finally, the cumulative duration of SD 
events was shortened in the DMT-treated group (140 ± 38 vs. 191 ± 42 
s, DMT vs. vehicle) (Fig. 3d). 
The share of Sig-1R activation in DMT-linked SD attenuation was 
explored by the application of a highly selective Sig-1R agonist PRE-084, 
or the use of a Sig-1R antagonist NE-100 alone or in combination with 
DMT. In the presence of PRE-084, the DMT-related reduction of SD 
amplitude and slower rate of depolarization were replicated (i.e. 
amplitude: − 16.2 ± 5.6 vs. − 20.1 ± 1.3 mV, PRE-084 vs. vehicle; rate of 
depolarization: − 2.26 ± 1.06 vs. − 3.48 ± 0.94 mV/s, PRE-084 vs. 
vehicle) (Fig. 3b–c), and the cumulative duration of SDs also tended to 
be shorter (149 ± 31 vs. 191 ± 42 s, PRE-084 vs. vehicle). NE-100 alone 
did not cause any notable change in SD amplitude, rate of depolarization 
or cumulative duration (e.g. amplitude: − 18.7 ± 2.6 vs. − 20.1 ± 1.3 
mV, NE-100 vs. vehicle) (Fig. 3b–d). In contrast with DMT applied alone, 
the co-application of NE-100 and DMT did not achieve any meaningful 
reduction of SD amplitude (− 19.2 ± 4.5 vs. − 20.1 ± 1.3 mV, NE- 
100+DMT vs. vehicle), depolarization rate (− 3.06 ± 1.18 vs. − 3.48 ±
0.94 mV/s, NE-100+DMT vs. vehicle), or cumulative duration (220 ±
12 vs. 191 ± 42 s, NE-100+DMT vs. vehicle) either (Fig. 3b–d). 
Next, we considered the possibility that DMT may activate 5-HTRs 
(Carnonaro and Gatch, 2016) and thereby inhibit SD (Guedes et al., 
2017). To this end, we administered the broad spectrum 5-HTR antag-
onist asenapine (Shadid et al., 2009) alone or co-applied with DMT. The 
amplitude of SD was significantly greater in the presence of asenapine 
alone as compared with vehicle (− 22.6 ± 2.6 vs. − 20.1 ± 1.3 mV, 
asenapine vs. vehicle). The co-application of DMT with asenapine 
re-established SD amplitude to control level (− 19.1 ± 1.3 vs. − 22.6 ±
2.6 mV, asenapine + DMT vs. asenapine) (Fig. 3b). The relative ampli-
tude of SD was greater in asenapine + DMT group with respect to DMT 
alone (− 22.6 ± 2.6 vs. − 16.5 ± 4.1 mV), albeit the difference was sta-
tistically not significant. These data collectively suggest that the 
SD-suppressing action of DMT was likely realized, at least in part, via 
Sig-1R activation. 
Of the three subsequent elements of the CBF response to SD (i.e. brief 
transient hypoperfusion, transient peak and late hyperemia, and long- 
lasting oligemia) (Ayata and Lauritzen, 2015) our analysis predomi-
nantly focused on the phase of hyperemia, which evolved reliably with 
Fig. 3. The impact of pharmacological treatments on the electrophysiological features of spreading depolarization (SD). a, Representative traces demonstrate that 
DMT treatment progressively attenuated the amplitude of subsequent SD events compared to vehicle-treated control, which action was prevented by the co- 
application of the Sig-1R antagonist NE-100. b, Similar to DMT, the highly specific Sig-1R agonist PRE-084 also decreased the amplitude of SDs. NE-100 co- 
application with DMT diminished DMT action. DMT co-applied with the broad-spectrum serotonin receptor antagonist asenapine achieved SD amplitude reduction 
compared to asenapine application alone. Data are given as mean ± stdev. The number of animals (mean of 3 SD events per animal) is indicated in each bar. The test 
of normality indicated that the distribution of data was not normal (Shapiro-Wilk test: df = 46 p = 0.001**). Consequently, a Kruskal-Wallis H test was applied (p <
0.01**), followed by an independent-samples Mann-Whitney U test (p < 0.05* and p < 0.01** vs. vehicle alone, p < 0.01$$ vs. DMT alone, p < 0.05# vs. asenapine 
alone). c, DMT and PRE-084 administration also decreased the rate of depolarization, which was prevented by both NE-100 and asenapine. d, DMT and PRE-084 
reduced the cumulative duration of SD events, while NE-100 (alone or in combination with DMT) exhibited the opposite effect. In “c-d”, data are given as mean ±
stdev. The number of animals (mean of 3 SD events per animal) is indicated in each bar. Statistical analysis indicated a normal distribution of data (c: Shapiro-Wilk 
test: df = 46 p = 0.360; d: Shapiro-Wilk test: df = 40 p = 0.383), therefore the analysis proceeded with a one-way ANOVA paradigm followed by a Fisher (least 
significant difference, LSD) post hoc test (p < 0.05* vs. vehicle alone, p < 0.05$ and p < 0.01$$ vs. DMT/PPRE-084 alone). 
Fig. 4. The impact of pharmacological treatments on the cerebral blood flow 
(CBF) response to spreading depolarization (SD). a, A trace representative of the 
vehicle group depicts the CBF response to the first (SD1) and recurrent SDs 
(rSD), as acquired with laser-Doppler flowmetry. b, The area under the curve 
(AUC) of the hyperemic component of the CBF response represents the 
magnitude of SD-related hyperemia, which was not modulated by any of the 
pharmacological treatments. Data are given as mean ± stdev. The number of 
animals (mean of 3 SD events per animal) is given in each bar. The test of 
normality indicated that the distribution of data was not normal (Shapiro-Wilk 
test: df = 44 p = 0.031*). Consequently, a Kruskal-Wallis H test was applied. 
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each SD (Fig. 4a). We narrowed down our analysis to recurrent SDs, 
because the kinetics of the CBF response to the first SD in a train is 
substantially different from the response given to recurrent SDs (Farkas 
et al., 2008; Ayata and Lauritzen, 2015) (Fig. 4a). 
In our experiments, the CBF response to recurrent SDs appeared to be 
resistant to all of the used pharmacological agents, including DMT or the 
selective Sig-1R agonist PRE-084. Like other parameters (i.e. amplitude 
or duration of hyperemia), the magnitude of hyperemia characterized by 
the area under the curve (AUC) was similar across various treatment 
regimes (Fig. 4b). 
3.3. Neuroprotection achieved with DMT 
Neuronal survival has been characterized by the surface area occu-
pied by NeuN-labeled neurons relative to the full field of view, in the 
somatosensory cortex and the hippocampus (Fig. 5a). With respect to 
naïve animals, no significant difference in NeuN immunopositivity was 
noted due to ischemia/hypoxia/reperfusion (e.g. somatosensory cortex: 
19.9 ± 1.9 vs. 19.3 ± 1.4%, vehicle vs. naive). Neuronal loss that might 
have been associated with SD was not found, either (e.g. somatosensory 
cortex: 19.5 ± 3.1 vs. 20.2 ± 3.2%, ipsi-vs. contralateral side to SD). 
Finally, DMT treatment exerted no meaningful effect on NeuN labeling 
(e.g. contralateral somatosensory cortex: 17.4 ± 2.0 vs. 19.9 ± 1.9%, 
DMT vs. vehicle). 
As neurons in the hippocampus CA1 and dentate gyrus (DG), the 
most vulnerable regions to ischemia are packed with pericarya so tightly 
that NeuN staining may not reveal individual cell loss, we labeled cells 
engaged in apoptotic cell death with CC3 immunostaining (Fig. 5b). 
Sections from naïve animals were virtually devoid of CC3-positive cells 
(i.e. DG: 163 ± 14 CC3+ cells per mm2), while CC3 labeled cell bodies 
were obvious in the cortex, hippocampus CA1 region, and particularly in 
the DG after ischemia/hypoxia/reperfusion in the vehicle group (DG: 
1649 ± 278 CC3+ cells per mm2) (Fig. 5b). The aggravation of apoptosis 
by recurrent SDs was anticipated in the cortex, where SDs propagated 
(Jahanbazi et al., 2018), but no lateralization of CC3 cell count was 
detected (vehicle group: 106 ± 46 vs. 104 ± 67 CC3+ cells per mm2, 
ipsi-vs. contralateral). For this reason, CC3+ cell counts obtained from 
the two hemispheres were averaged for each region. Importantly, 
significantly fewer CC3 labeled apoptotic cells were counted in the 
DMT-treated compared to vehicle-treated animals in the somatosensory 
cortex (66 ± 33 vs. 105 ± 56 CC3+ cells per mm2, DMT vs. vehicle), 
hippocampal CA1 region (532 ± 268 vs. 893 ± 249 CC3+ cells per mm2, 
DMT vs. vehicle) and DG (1367 ± 311 vs. 1649 ± 278 CC3+ cells per 
mm2, DMT vs. vehicle) (Fig. 5b). 
In addition to apoptosis, ischemic/hypoxic stress may induce fer-
roptosis, an alternative pathway of programmed cell death that has been 
recognized recently (Dolma et al., 2003; Stockwell et al., 2017). The 
typical hallmark of ferroptosis is the iron-dependent accumulation of 
lipid hydroperoxides, hence the cellular process can be detected by 
4-HNE immunohistochemistry (Cao and Dixon, 2016). Ferroptosis was 
obvious in selected neurons in the hippocampus CA1 and dentate gyrus 
(Fig. 5c). The number of ferroptotic cells tended to be lower in the 
DMT-treated CA1 (4.53 ± 0.39 vs. 6.13 ± 2.49 count/mm2, DMT vs. 
vehicle), but this difference was statistically not significant. Also, the 
cell counting approach was not fully reliable due to the cell density in 
the CA1 pyramidal cell layer and the dentate gyrus granule cell layer (i. 
Fig. 5. Representative light microscopic images of immuno-labeled sections and bar charts demonstrate neuroprotection achieved by DMT administration in cortical 
(sensory cortex and hippocampus) and subcortical gray matter (striatum). a, No changes were observed in the density of NeuN-labeled neurons, either due to 
ischemia/reperfusion, or DMT treatment. b, Cleaved caspase-3 (CC3) positive apoptotic cells in the granule cell layer of the dentate gyrus (DG) were obvious, and 
were also present to a lesser degree in the hippocampus CA1 region after ischemia/reperfusion in the vehicle group. DMT administration reduced the number of CC3- 
positive apoptotic cells. Cell count is given for 1 mm2 surface area. c, Representative sections labeled for 4-hydroxynonenal (4-HNE) indicate ferroptotic cell death 
(arrowheads) in the hippocampus dentate gyrus (DG, image pair to the left) and CA1 region (image pair to the right). Note that even though the number of 4-HNE- 
positive cells was not significantly different between experimental groups, the optical density of the perinuclear cytoplasm was considerably lower after DMT 
treatment (bar chart below). d, Glial fibrillary acidic protein (GFAP)-positive astrocytes were lost following ischemia/reperfusion in the vehicle group, but were 
partially rescued by DMT treatment. e, Prominent microglia activation was detected in the cortex ipsilateral to SD-elicitation and the craniotomies (M. Tóth et al., 
2020), which was not modulated by DMT application. In the bar charts of Panels “a-d”, data are presented as mean ± stdev, sample size is given in each bar. 
Horizontal dotted lines indicate levels measured in naïve rats (n = 3). Statistical analysis was conducted using a one-way (e.g. 4-HNE) or two-way ANOVA model with 
treatment and region (e.g. NeuN, GFAP, CC3), or side and treatment (Iba-1) as factors (p < 0.05*; p < 0.01**). 
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e. discriminating individual cells carries uncertainty). However, the 
lower intensity of the 4-HNE staining in the perinuclear cellular cyto-
plasm after DMT treatment was conspicuous and indicated an 
anti-ferroptotic effect of DMT (0.025 ± 0.002 vs. 0.048 ± 0.012, DMT 
vs. vehicle) (Fig. 5c). 
Because astrocytes have been widely known to support neuronal 
function under ischemia (Rossi et al., 2007), and GFAP-positive proto-
plasmic astrocytes may become selectively vulnerable to ischemic con-
ditions (Lukaszevicz et al., 2002), we have explored whether DMT has 
the potential to protect astrocytes. We used GFAP immunocytochemistry 
to label astrocytes (Fig. 5d). The relative area occupied by GFAP 
immunolabeled compartments considerably decreased after ischemia/-
hypoxia/reperfusion compared to naive animals, which reduction was 
counteracted by DMT-treatment in the cortex and striatum (cortex: 3.2 
± 1.9 vs. 1.5 ± 0.3 vs. 4.7 ± 0.9%, striatum: 2.3 ± 1.1 vs. 0.9 ± 0.2 vs. 
3.2 ± 1.6%, DMT vs. vehicle vs. naive), but not in the hippocampus (i.e. 
CA1 stratum oriens 10.6 ± 4.9 vs. 11.1 ± 5.8 vs. 15.5 ± 2.7%, DMT vs. 
vehicle vs. naive) (Fig. 5d). 
Ischemic insults trigger microglial activation and neuro-
inflammatory reaction that may be modulated via Sig-1Rs (Szabo et al., 
2016; Jia et al., 2018). In the cerebral cortex ipsilateral to the craniot-
omies and SD initiation, decreasing microglial arborization was ex-
pected to denote the amplification of microglial activation (Varga et al., 
2020; M. Tóth et al., 2020). The current data confirm the previous ob-
servations by showing less dense microglia ramification in the ipsilateral 
cortex compared to the contralateral side (vehicle group: 106.6 ± 50.5 
vs. 194.3 ± 95.6, ipsi-vs. contralateral) (Fig. 5e). Yet, the administration 
of DMT did not exert any distinguishable effect on the microglial 
ramification index (i.e. ipsilateral cortex: 89.5 ± 37.4 vs. 106.6 ± 50.5 
DMT vs. vehicle) (Fig. 5e). 
3.4. Receptor binding, tissue DMT content and Sig-1R co-localization 
The binding affinities of the compounds for the Sig-1R were deter-
mined in competitive binding assays. The assay conditions were vali-
dated with various Sig-1R ligands and the following order of potency for 
Sig-1R binding was found: (+)-pentazocine > fluvoxamine > PRE-084 
(Fig. 6a). All three compounds exhibited nanomolar Sig-1R affinities and 
induced a similar maximal displacement (around 90–100%). To eval-
uate if DMT exerts its action by binding to Sig-1R, the Sig-1R binding 
affinity of DMT was investigated in the absence or presence of asena-
pine, a potent serotonin- and dopamine receptor antagonist (Shadid 
et al., 2009). 
Competition binding assays in rat brain membrane homogenate 
against the Sig-1R specific radioligand [3H](+)-pentazocine revealed 
that DMT bound the Sig-1R with an inhibitory constant value of 15.1 
μM. This is in agreement with the results of Fontanilla et al. (2009), who 
found that DMT bound the Sig-1R at low micromolar concentrations (Kd 
= 14.7 μM) in guinea pig liver membrane homogenate. Asenapine could 
not displace the radioligand from the [3H](+)-pentazocine binding sites 
(10 μM asenapine reduced total specific binding of the radioligand to 
82%) indicating the lack of specific affinity of asenapine for the Sig-1R 
(Fig. 6a1). When 10 μM asenapine was added to DMT, no significant 
difference was observed in the Sig-1R binding affinity of DMT, indi-
cating that asenapine did not influence the Sig-1R binding of DMT 
(Fig. 6a2). 
Since DMT is rapidly degraded by monoamine oxidases (MAO) in 
peripheral tissues (Burchett and Hicks, 2006), we evaluated blood 
plasma and brain tissue DMT content with 2D-LC-MS/MS (Körmöczi 
et al., 2020). Importantly, DMT administered at a dose of 1 mg/kg/h by 
i.v. infusion was clearly detectable in blood plasma measured 50 min 
Fig. 6. Sig-1R ligand binding affinities in rat brain homogenates, blood plasma and brain tissue DMT content, and the cellular localization of Sig-1R in the rat 
cerebral cortex. a, Competitive binding curves of various Sig-1R ligands against the radioactive Sig-1R ligand [3H](+)-pentazocine (A1) and of DMT in the absence or 
presence of 10 μM asenapine (A2) in rat brain membrane homogenates. Curves are shown as percent specific binding (10 μM haloperidol). b, Blood plasma and brain 
tissue were enriched in DMT after intravenous infusion, as measured by two-dimensional liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry 
(2D-LC-MS/MS). In contrast, DMT was undetectable in blood plasma and brain tissue of control rats by 2D-LC-MS/MS (data not shown). c, Immuno-labeled brain 
slices demonstrate the perinuclear localization of Sig-1R in NeuN-labeled cortical pyramidal cells (epifluorescent and confocal microscopic images; c1). In GFAP- 
positive astrocytes, Sig-1R was seen in the perinuclear soma, and in processes (confocal microscopic image; c2). Both the soma and processes of Iba-1-labeled 
microglia were endowed with Sig-1Rs (confocal microscopic image; c3). 
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after the initiation of DMT infusion (90.5 ± 37.9 ng/mL, ca. 0.5 μM), and 
in the brain tissue sampled upon the termination of the experimental 
protocol (4.6 ± 1.9 ng/g tissue, ca. 0.02 μmol/kg) (Fig. 6b). Potential 
endogenous DMT concentration in the vehicle group remained below 
detection level. 
Finally, to identify cell types that may be targeted by DMT, we co- 
localized Sig-1R with neurons, astrocytes, and microglia with fluores-
cent immunocytochemistry in naïve rats. Sig-1Rs were expressed 
abundantly in neurons (Fig. 6c1), and were also associated with astro-
cytes (Fig. 6c2), and resting microglia (Fig. 6c3). 
4. Discussion 
The objective of our current study was to explore whether DMT 
administration achieves neuroprotection via Sig-1R activation in the 
acute phase of experimental, transient, cerebral forebrain ischemia, 
aggravated by the recurrent induction of SDs and a subsequent transient 
hypoxic episode. DMT is a natural, endogenous Sig-1R ligand, which is 
thought to pose as an advantage of DMT application as opposed to other, 
synthetic Sig-1R agonists. 
The impact of DMT treatment on physiological variables was 
screened comprehensively, because single intravenous doses of DMT 
have been reported to cause sympathetic activation, and to prominently 
increase blood pressure and heart rate within minutes after adminis-
tration (Strassman and Qualls, 1994). In our experiments, DMT exerted 
no obvious impact on cardiovascular or cerebrovascular function 
(Fig. 2), which may be attributed to the continuous, slow infusion of 
DMT (rather than a bolus application), controlled anesthesia, or their 
combination. The absence of apparent cardio- or cerebrovascular effects 
in our study proved to be favorable, as the neuroprotective potential of 
DMT could be assessed free of any marked changes in physiological 
variables. 
Recurrent SD events have served here the evaluation of the ischemic 
neuroprotective potential of DMT, linked to Sig-1R activation. SD is the 
synchronized depolarization of a critical bulk of tissue in the cerebral 
gray matter, which is thought to be triggered by local metabolic supply- 
demand mismatch under ischemia (von Bornstädt et al., 2015). SD 
propagates over the cerebral cortex at a slow rate of a few mm/min, by 
progressively involving neighboring tissue in the depolarization (Leao, 
1944; Somjen, 2001). Further, SD is accompanied by a CBF response 
dominated typically by a remarkable hyperemic element (Fig. 4a), 
which serves the replenishment of ATP necessary for timely repolari-
zation behind the SD wave front (Ayata and Lauritzen, 2015). Impor-
tantly, recurrent SDs have been recognized as a universal principle of 
lesion progression in the injured cerebral gray matter (Hartings et al., 
2017; Dreier et al., 2017)], and SD suppression has been considered as a 
promising therapeutical approach to improve neurological outcome 
after acute brain injury (Carlson et al., 2018, 2020; Klass et al., 2018). 
In our current experiments, SD amplitude, the rate of depolarization 
and cumulative SD duration were reduced under intravenous DMT 
administration, exhibiting the SD limiting impact of DMT. Further, the 
application of the selective Sig-1R agonist PRE-084 reproduced the SD 
hampering action of DMT, and the Sig-1R antagonist NE-100 co-applied 
with DMT diminished the DMT-related SD inhibition (Fig. 3). These 
results collectively suggest that DMT may impede SD evolution by Sig- 
1R activation. The implication of Sig-1Rs is supported by previous re-
ports demonstrating that dextromethorphan or carbetapentane – two 
ligands known as Sig-1R agonists – reproducibly and reliably blocked SD 
occurrence in live brain slice preparations (Anderson and Andrew, 2002; 
Anderson et al., 2005; Church et al., 2005). 
Recurrent SDs may accelerate ischemic lesion maturation because SD 
is associated with an intracellular rise of calcium (Siesjö and Bengtsson, 
1989; Reinhart and Shuttleworth, 2018), which potentially contributes 
to the calcium overload known to initiate ischemic neurodegeneration 
(Szydlowska and Tymianski, 2010). Indeed, the non-competitive NMDA 
receptor antagonist ketamine inhibited SD evolution with a concomitant 
reduction of neuronal calcium content in brain slice preparations 
(Reinhart and Shuttleworth, 2018), and voltage-gated calcium channel 
blockers reduced SD amplitude in anesthetized rats (Richter et al., 2002; 
Szabó et al., 2019), similar to that seen here. Intriguingly, Sig-1R ago-
nism was shown to attenuate the NMDA receptor activation-linked 
calcium response in cultured neurons (Klette et al., 1997), and to 
depress calcium currents with a corresponding inactivation of neuronal 
voltage-gated calcium channels (Zhang et al., 2002). On the basis of 
these and our experimental data together, we postulate that DMT in our 
experiments possibly inhibited SD via Sig-1R-linked modulation of 
intracellular calcium homeostasis. 
The suggestion that DMT predominantly achieved SD inhibition by 
Sig-1R activation – rather than through 5-HTR binding (Yanai et al., 
1986; Deliganis et al., 1991) – is also substantiated by our finding that 
DMT counteracted the SD potentiating effect of asenapine (Fig. 3), an 
antagonist of multiple 5-HTRs (Shahid et al., 2009). In other words, 
when 5-HTRs were occupied by asenapine, DMT still reduced SD 
amplitude with respect to the condition when asenapine was given 
alone. Of note, our results that 5-HTR antagonism increased SD ampli-
tude (Fig. 3) are complementary to previous reports showing that 
ablation of the dorsal raphe serotonergic neurons accelerated SD prop-
agation in the cerebral cortex (Cui et al., 2013), electrical stimulation of 
the dorsal raphe or the administration of sumatriptan, a 5-HT1D receptor 
agonist decelerated SD (Guedes et al., 2017), and sumatriptan also 
suppressed SD evolution in experimental focal cerebral ischemia (Mies 
et al., 1998). Thus, serotonergic activity appears to restrain SD, and, 
conversely, serotonergic deficiency may augment SD. 
Finally, we evaluated the impact of the pharmacological treatments 
on the CBF response to SD, especially because it is unknown whether and 
how DMT might alter neurovascular coupling. Another consideration 
has been that the CBF response to SD in the hypoperfused cerebral cortex 
is understood to be insufficient to meet the metabolic demand of the 
nervous tissue (Dreier, 2011; Hoffmann and Ayata, 2013), therefore the 
pharmacological enhancement of the SD-associated CBF response may 
support neuronal survival in tissue at risk (Dreier et al., 1998; Varga 
et al., 2020). DMT treatment in our experiments, however, did not alter 
the SD-related hyperemia (Fig. 4). Furthermore, none of the other agents 
used (the Sig-1R agonist PRE-084, the Sig-1R antagonist NE-100 or the 
5-HTR antagonist asenapine) proved to be effective at modulating the 
SD-associated CBF response in any meaningful way (Fig. 4). The 
implication of Sig-1R in the mediation of the SD-associated hyperemia 
has been previously unattended, and our current results do not support 
the notion that Sig-1R signaling may augment the SD-related CBF 
response, at least not under ischemic conditions. On the other hand, the 
5-HT1D/1B receptor agonist zolmitriptan increased, while the 5-HT2A/2C 
receptor antagonist ritanserin attenuated the amplitude of hyperemia in 
the optimally perfused cerebral cortex (Gold et al., 1998). The 
non-specific 5-HTR antagonist asenapine would then be expected to 
curb the hyperemic response to SD, but exerted no effect. The condition 
that SDs occurred here in ischemic tissue could have possibly overridden 
physiological blood flow regulation with SD (Varga et al., 2016) – 
indeed, ischemia is known to impair neurovascular coupling (Jackman 
and Iadecola, 2015). Taken together, we assume that Sig-1R or 
5-HTR-based modulation of the CBF response to SD in the ischemic ce-
rebral cortex proves to be ineffective. 
Several groups have reported independently that Sig-1R agonism 
successfully reduced infarct size estimated 24 h or a number of days after 
an episode of experimental focal cerebral ischemia (Ajmo et al., 2006; 
Omi et al., 2014; Sato et al., 2014; Nardai et al., 2020). Therefore, we 
proceeded to investigate the neuroprotective potential of DMT at his-
tological level as early as 2 h after ischemia induction and 1 h after 
reperfusion initiation (Fig. 1). In our experiments, NeuN staining did not 
reveal significant loss of neurons, possibly because the end point was too 
early to detect massive neurodegeneration (i.e. infarct maturation), and 
the staining is too dense to be sensitive for the selective loss of scattered, 
individual cells. However, the network of GFAP-positive astrocytes 
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became remarkably sparser after ischemia/reperfusion as compared to 
naïve samples (Fig. 5d). This is consistent with the loss of the GFAP 
signal and swelling of protoplasmic astrocytes in the first hours after the 
onset of experimental focal cerebral ischemia, suggestive of astrocyte 
dysfunction (Lukaszevicz et al., 2002). Importantly, the GFAP signal has 
been partially restored in our experiments when DMT was administered 
and Sig-1R co-localized with astrocytes (Fig. 6c), which is complemen-
tary to a previous report demonstrating that Sig-1R agonism augmented 
astrocyte survival screened 96 h after ischemia onset (Katnik et al., 
2016). These results indicate that DMT preserved the integrity of the 
astrocyte network – and presumably function – by Sig-1R receptor 
activation. 
The labeling of microglia replicated our previous results that 
microglia activation – characterized by the less dense arborization of 
microglial processes – appeared more pronounced in the cortex ipsilat-
eral to SD elicitation (Fig. 5e) (Tóth et al., 2020; Varga et al., 2020). As 
we argued previously, the recurrence of SDs and the procedure of 
trepanation both contribute to the enhanced activation of microglia 
(Tóth et al., 2020; Varga et al., 2020). DMT has emerged to curtail in-
flammatory responses, substantiated by the reduced production of 
pro-inflammatory cytokines by provoked human primary 
monocyte-derived dendritic cells (Szabo et al., 2014), and the lower 
pro-inflammatory cytokine serum levels in rats suffering of stroke 
(Nardai et al., 2020). Moreover, Sig-1R agonism with 1,3-di-(2-tolyl) 
guanidine (DTG) inhibited the activation and cytokine release of 
cultured microglia provoked by endotoxin (Hall et al., 2009). These data 
and the expression of Sig-1R in microglia (Fig. 6) (Nardai et al., 2020) 
led to the assumption that DMT treatment may target microglia. Yet, in 
the current experiments, DMT had no discernible impact on microglia 
activation (Fig. 6c). Likewise, Sig-1R activation achieved no change in 
Iba-1 immuno-labeling and cerebral cytokine production in a focal ce-
rebral ischemia model (Ruscher et al., 2012). Taken together, we pro-
pose that DMT treatment may suppress the activation of dendritic cells 
or microglia provoked with direct inflammatory stimuli in culture, but 
may not be as potent to inhibit microglia activation caused by ischemia 
or SD in anesthetized rodents. 
Apoptotic cell death has emerged as an especially relevant target to 
investigate, because Sig-1R agonism has been revealed to suppress ER 
stress-related apoptosis (Omi et al., 2014; Sato et al., 2014; Zhao et al., 
2019). Concurring with the evidence that DMT activates Sig-1Rs (Fon-
tanilla et al., 2009), and in line with the above data on the anti-apoptotic 
effect of Sig-1R activation, DMT treatment reduced here the number of 
CC3-positive apoptotic cells, especially in the hippocampus. On the basis 
of their histological position, a fraction of these cells must have been 
neurons (Fig. 5b), which cell type is endowed with Sig-1Rs (Fig. 6c). The 
early activation of CC3 here must be attributed to the ischemia/r-
eperfusion and anoxia rather than SD, because we did not identify any 
lateralization of apoptosis that would correspond to SD. This is consis-
tent with previous findings that the incomplete global forebrain 
ischemia model is sufficient alone to produce neuronal injury (Farkas 
et al., 2007). The time course of caspase activation is expected to vary 
around 15–30 min as measured in single cells (HeLa D98 cells) in culture 
(Rehm et al., 2002), but may exceed this time dependent on the stimulus 
in neuron populations in vivo (Teschendorf et al., 2008). It is plausible 
that the time window taken here is too short to appreciate the impact of 
SD on CC3 activation and its pharmacological inhibition in the other-
wise ischemic brain tissue. 
Similar to the impact of DMT treatment on apoptosis, our 4-HNE 
staining showed that DMT administration reduced the intensity of fer-
roptosis, as well (Fig. 5c). It is a novel observation, consistent with the 
finding that Sig-1R activation or overexpression inhibits the generation 
of reactive oxygen species (Hayashi, 2019). 
Finally, in support of our in vivo functional and histological results, 
we set out to test DMT binding affinity to rat cerebral Sig-1R, because 
the reference assay we relied on had been conducted on guinea pig liver 
homogenates (Fontanilla et al., 2009). Our competition binding assay 
revealed that DMT bound cerebral Sig-1R at an inhibitory constant value 
of 15.1 μM, which corresponds to that measured in guinea pig liver 
membrane homogenates (Kd = 14.7 μM) (Fontanilla et al., 2009), and 
substantiates our in vivo pharmacological data with confidence. We also 
measured the DMT content of blood plasma and brain homogenates to 
confirm that DMT was present to exert biological effects. Previously we 
reported that our analytical method was not sensitive enough to detect 
endogenous DMT, but was reliable to measure exogenous tissue DMT 
content (Körmöczi et al., 2020). Here, we successfully confirmed the 
presence of exogenous DMT in our samples in the range of 4–90 ng/g or 
ng/mL sample (ca. 0.02 μmol/kg for brain or 0.5 μM for plasma; Fig. 6b). 
Since, due to receptor reserves, fractional occupancy of a receptor pool 
may still generate a maximal biological effect, the micromolar Sig-1R 
affinity of DMT may be sufficient to elicit a Sig-1R mediated effect at 
the measured DMT concentrations, especially in the presence of the 
off-target antagonist asenapine. It was also found that asenapine did not 
bind to Sig-1R and did not influence the Sig-1R binding of DMT. The 
DMT content in our samples is most probably an underestimation of the 
true concentration, because DMT must have been rapidly degraded 
during the procedure of harvesting samples (Burchett and Hicks, 2006), 
especially when extracting brain tissue (i.e. the half-life of DMT was 
found to be 5–6 min in rat brain tissue) (Sitaram et al., 1987). 
In conclusion, here we present novel observations that DMT 
administered with therapeutic purpose in the early phase of cerebral 
ischemia impedes the evolution of recurrent SDs, which are known to 
jeopardize the survival of viable penumbra tissue in ischemic stroke 
(Mies, 1998; Hartings et al., 2017). Further, we demonstrate that DMT 
protects astrocytes against ischemic injury, and suppresses 
ischemia/reperfusion-related apoptosis in the nervous tissue. As an 
original observation, we show that DMT appears to counteract ferrop-
totic cell death linked to oxidative stress. Finally, we have accumulated 
compelling evidence that DMT most likely achieves its neuroprotective 
effect via Sig-1R activation. The beneficial effects of DMT manifested at 
regular cardiovascular function and unrestored cerebral perfusion. 
Overall, our data support the notion, that the timely administration of 
DMT may be considered as an adjuvant pharmacological therapy in the 
treatment of acute cerebral ischemic injury (Szabo and Frecska, 2016), 
especially because of reported low risk of toxicity (Carbonaro and Gatch, 
2016). 
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Farkas, E., Obrenovitch, T.P., Institóris, Á., Bari, F., 2011. Effects of early aging and 
cerebral hypoperfusion on spreading depression in rats. Neurobiol. Aging 32 (9), 
1707–1715. https://doi.org/10.1016/j.neurobiolaging.2009.10.002. 
Fontanilla, D., Johannessen, M., Hajipour, A.R., Cozzi, N.V., Jackson, M.B., et al., 2009. 
The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 
receptor regulator. Science 323 (5916), 934–937. https://doi.org/10.1126/ 
science.1166127. 
Frecska, E., Szabo, A., Winkelman, M.J., Luna, L.E., McKenna, D.J., 2013. A possibly 
sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, 
regeneration, and immunity. J. Neural. Transm. 120 (9), 1295–1303. https://doi. 
org/10.1007/s00702-013-1024-y. 
Ghanbari, R., El Mansari, M., Shahid, M., Blier, P., 2009. Electrophysiological 
characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)- 
adrenergic and D(2) receptors in the rat brain. Eur. Neuropsychopharmacol 19 (3), 
177–187. https://doi.org/10.1016/j.euroneuro.2008.11.001. 
Gold, L., Back, T., Arnold, G., Dreier, J., Einhäupl, K.M., et al., 1998. Cortical spreading 
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Tóth O, M., Á, Menyhárt, Varga, V.É., Hantosi, D., Ivánkovits-Kiss, O., et al., 2020. 
Chitosan nanoparticles release nimodipine in response to tissue acidosis to attenuate 
spreading depolarization evoked during forebrain ischemia. Neuropharmacology 
162, 107850. https://doi.org/10.1016/j.neuropharm.2019.107850. 
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